1. Home
  2. SCLX vs KOPN Comparison

SCLX vs KOPN Comparison

Compare SCLX & KOPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • KOPN
  • Stock Information
  • Founded
  • SCLX 2011
  • KOPN 1984
  • Country
  • SCLX United States
  • KOPN United States
  • Employees
  • SCLX N/A
  • KOPN N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • KOPN Semiconductors
  • Sector
  • SCLX Health Care
  • KOPN Technology
  • Exchange
  • SCLX Nasdaq
  • KOPN Nasdaq
  • Market Cap
  • SCLX 81.7M
  • KOPN 85.7M
  • IPO Year
  • SCLX N/A
  • KOPN 1992
  • Fundamental
  • Price
  • SCLX $0.42
  • KOPN $1.28
  • Analyst Decision
  • SCLX Strong Buy
  • KOPN Strong Buy
  • Analyst Count
  • SCLX 3
  • KOPN 3
  • Target Price
  • SCLX $11.33
  • KOPN $2.67
  • AVG Volume (30 Days)
  • SCLX 184.3K
  • KOPN 1.7M
  • Earning Date
  • SCLX 01-07-2025
  • KOPN 11-12-2024
  • Dividend Yield
  • SCLX N/A
  • KOPN N/A
  • EPS Growth
  • SCLX N/A
  • KOPN N/A
  • EPS
  • SCLX N/A
  • KOPN N/A
  • Revenue
  • SCLX $50,833,000.00
  • KOPN $44,266,305.00
  • Revenue This Year
  • SCLX $32.77
  • KOPN $22.10
  • Revenue Next Year
  • SCLX $50.71
  • KOPN $14.34
  • P/E Ratio
  • SCLX N/A
  • KOPN N/A
  • Revenue Growth
  • SCLX 9.41
  • KOPN 0.60
  • 52 Week Low
  • SCLX $0.40
  • KOPN $0.56
  • 52 Week High
  • SCLX $2.63
  • KOPN $2.82
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 29.75
  • KOPN 64.90
  • Support Level
  • SCLX $0.43
  • KOPN $1.21
  • Resistance Level
  • SCLX $0.51
  • KOPN $1.48
  • Average True Range (ATR)
  • SCLX 0.06
  • KOPN 0.11
  • MACD
  • SCLX -0.01
  • KOPN 0.00
  • Stochastic Oscillator
  • SCLX 7.30
  • KOPN 55.56

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

Share on Social Networks: